DUOPHARMA BIOTECH BERHAD INVESTOR RELATIONS BRIEFING 1
Disclaimer This presentation may contain forward-looking statements by Duopharma Biotech Berhad that reflect management’s current expectations, beliefs, intentions or strategies regarding the future and assumptions in light of currently available information. These statements are based on various assumptions and made subject to a number of risks, uncertainties and contingencies. Actual results, performance or achievements may differ materially and significantly from those discussed in the forward-looking statements. Such statements are not and should not be construed as a representation, warranty or undertaking as to the future performance or achievements of Duopharma Biotech Berhad and Duopharma Biotech Berhad assumes no obligation or responsibility to update any such statements. No representation or warranty (either express or implied) is given by or on behalf of Duopharma Biotech Berhad or its related corporations (including without limitation, their respective shareholders, directors, officers, employees, agents, partners, associates and advisers) (collectively, the " Parties ") as to the quality, accuracy, reliability or completeness of the information contained in this presentation (collectively, the " Information "), or that reasonable care has been taken in compiling or preparing the Information. None of the Parties shall be liable or responsible for any budget, forecast or forward-looking statements or other projections of any nature or any opinion which may have been expressed in the Information. The Information is and shall remain the exclusive property of Duopharma Biotech Berhad and nothing herein shall give, or shall be construed as giving, to any recipient(s) or party any right, title, ownership, interest, licence or any other right whatsoever in or to the Information herein. The recipient(s) acknowledges and agrees that this presentation and the Information are confidential and shall be held in complete confidence by the recipient(s). No part of this presentation is intended to or construed as an offer, recommendation or invitation to subscribe for or purchase any securities in Duopharma Biotech Berhad . 2
Jo Journey of f Duopharma Biotech Berhad On 28 In 2005, In 2015, CCMB December Chemical On 25 underwent a 2017, CCM Company of February In 2006, corporate Duopharma Malaysia In 2007, CCMD 2019, CCMD Duopharma restructuring. de-merged Berhad acquired the has changed was rebranded from CCMB. (“CCMB”) assets and its name to to CCM acquired brands of Duopharma All of its Therefore, Duopharma Duopharma , a Malayan Biotech pharmaceutical CCMD became Biotech pharmaceutical Pharma. Berhad subsidiaries an (“CCMD”). company that (“ Duopharma were placed independent was established Biotech”). under CCMD. public listed since 1979. company. 3
Implications of Im f the De-merger We are REQUIRED to We are REQUIRED We are UNABLE to We are REQUIRED to change the company to have our own carry CCM brand / establish our own vision name and its corporate identity name and mission subsidiaries 4
Logo Description Colour of the logo ▪ Logo is rendered in bold red, the colour of passion Letter ‘D’ and ‘B’ inside the hexagon ▪ D and B stand for ‘ Duopharma ’ and ‘Biotech ’ Shape ▪ Modern ▪ Symbolises innovation across every aspect of the business ▪ Six sides represent the company’s six core values Name of Duopharma at the bottom ▪ Expressed in a font that perfectly balances rounded shapes ▪ “Duo” represents the company’s two main businesses – prescribed medicine and consumer healthcare product 5
New Vision, Mission and Tagline New VISION Providing smarter solutions for a healthier life New MISSION A leading Healthcare Group providing quality and innovative solutions New TAGLINE Smarter Solutions. Healthier Life. 6
Change of f Name of Company Old Company Name New Company Name Status Duopharma Marketing Effective from 26 December CCM Pharmaceuticals Sdn. Bhd. 2018 Sdn. Bhd. Duopharma Manufacturing Effective from 26 December Upha Pharmaceutical (Bangi) Sdn. Bhd. 2018 Manufacturing (M) Sdn. Bhd. Duopharma Innovation Effective from 26 December Sdn. Bhd. 2018 Innovax Sdn. Bhd. Duopharma HAPI Sdn. Bhd. Effective from 26 December CCM Biopharma Sdn. Bhd. 2018 Duopharma Effective from 26 December Manufacturing 2018 CCM Pharma Sdn. Bhd. (Glenmarie) Sdn. Bhd. 7
Change of f Name of Company Old Company Name New Company Name Status Duopharma (M) Sendirian Duopharma (M) Sendirian No change to company Berhad Berhad name Sentosa Pharmacy Sdn. Sentosa Pharmacy Sdn. No change to company Bhd. Bhd. name Unique Pharmacy (Penang) Unique Pharmacy No change to company Sdn. Bhd. (Penang) name Sdn. Bhd. Negeri Pharmacy Sdn. Bhd. Negeri Pharmacy Sdn. No change to company Bhd. name Unique Pharmacy (Ipoh) Unique Pharmacy (Ipoh) No change to company Sdn. Bhd. Sdn. Bhd. name 8
Change of f Name of Company Old Company Name New Company Name Status CCM Pharmaceuticals (S) Duopharma (Singapore) Effective from 4 January Pte. Ltd. Pte. Ltd. 2019 CCM International DB (Philippines), Inc. Effective from 15 February (Philippines), Inc. 2019 CCM Duopharma Biotech Duopharma Biotech Effective from 25 February Berhad Berhad 2019 9
Corporate Structure 10
Shareholding Stru ructure Others, 41.3% PNB, 46.7% DPHARMA (Stock Code – 7148) Amanahraya Trustees Market capitalization on 30.04.2019 Berhad,ASB, = RM 933 mil EPF, 7.8% 4.2% Share price = RM 1.41 Note: Shareholding as at 31 January 2019 11
Board of f Directors Executive Director Senior Independent Non- Non-Independent & Non- Executive Director Executive Chairman Group Managing Director Tan Sri Datin Paduka Siti Dato' Mohamad Kamarudin Encik Leonard Ariff bin Sa'diah Binti Sh Bakir bin Hassan Abdul Shatar Independent Non- Independent Non- Independent Non- Executive Director Executive Director Executive Director Datuk Seri Rohani Parkash Puan Zaiton binti Encik Razalee bin Amin binti Abdullah Jamaluddin Independent and Non- Independent Non- Non-Independent and Executive Director Executive Director Non-Executive Dato' Eisah Binti A. Datuk Nik Moustpha bin Datuk Mohd Radzif Bin Rahman Hj Nik Hassan Mohd Yunus 12
Board of f Directors STRUCTURE Board of Directors Nomination and Risk Management and Audit and Integrity Remuneration Halal Committee Sustainability Committee Committee Committee Chairman: Datuk Nik Moustpha bin Hj Nik Chairman: Encik Razalee Chairman: Dato’ Chairman: Datuk Mohd Hassan bin Amin Mohamad Kamarudin bin Radzif bin Mohd Yunus Hassan 13
Group Management Committee 14
Financial Highlights RM’ million 70 600 RM’million (in RM'million) 2016 2017 2018 60 500 50 Non-current 400 295.3 348.6 469.0 assets 40 300 30 Current assets 366.2 356.6 367.3 200 20 Equities 454.5 479.9 481.0 100 10 Liabilities 206.9 225.4 355.3 0 0 2016 2017 2018 Gearing 0.25x 0.27x 0.51x PBT 31.5 51.8 59.7 PAT 26.8 42.5 47.6 Revenue 312.9 468.0 498.7 Return on Equity 5.9% 8.8% 9.9% PBT PAT Revenue Internal Restructuring completed on 24 May 2018 enables the Group to be more nimble in securing potential business opportunities and more tax efficient. 15
Fin inancial Hig ighlights – Segmental Sale les Export Export Export 8% 8% 12% Local Local (Government) Local Local (Government) 34% (Government) Local (Private) 54 % 49% 50% Local (Private) 42% 39% (Private) 43% 54% FY 2018 Revenue : FY 2016 Revenue : FY 2017 Revenue : RM 498.72 mil RM 312.94 mil RM 467.99 mil Note: Duopharma Biotech’s top export markets in FY2018 (% based on export revenue) : 1.Singapore – 22.6% (RM9.3mil) 2.Philippines – 21.1% (RM8.7mil) 3.Middle East – 18.4% (RM7.6mil) 16
Key Highlights KEY HIGHLIGHTS No. 1 local pharma company in terms of volume and No.2 in terms of sales and market share (Source: IQVIA Report, December 2018). Continuous collaboration and partnering with key pharma players i.e. Biocon, PanGen Biotech, Natco & Becton Dickinson. Successfully launched a pre-filled format for an insulin glargine, Basalog One. Expanded our Hepatitis C portfolio with products from Natco. Flavettes regained its leadership as the No.1 supplement in the Adults Vitamin C market in Malaysia with the Effervescent range overtaking all other brands in terms of market share. Penetrated four new international markets and achieve all-time high sales. Completed and commissioned Malaysia’s first Highly Potent Active Pharmaceutical Ingredients (HPAPI) manufacturing facility. Completed EPO Phase III clinical trials in April 2017. Completed Malaysia’s first biological pre-filled syringe line to manufacture the biosimilar. Obtained Registration approval for the product called Erysaa from the National Pharmacy Regulatory Agency (NPRA) on 31 January 2019. Won a contract from the government to supply Daclatasvir. 17
Recommend
More recommend
